Search for content, post, videos

Active Biotech Stocks in the Spotlight: Achillion Pharmaceuticals, Inc.(ACHN), Threshold Pharmaceuticals, Inc.(THLD), Keryx Biopharmaceuticals(KERX)

U.S. stocks were mixed on Thursday as the Dow Jones Industrial Average halted a 3-day winning streak, retreating from a considerable Santa Claus Rally from the previous session on the eve of the Christmas holiday.

Energy and retail stocks remained in focus, as U.S. crude futures continued their bounce off multi-year lows and frenzied shoppers crowded malls nationwide for last-minute gifts. On Thursday, WTI crude was on track for its fourth straight winning session, hovering at two-week highs near $38 a barrel. A session earlier, Texas Long Sweet futures surged amid an unexpected draw in U.S. crude stockpiles last week.

For the week, U.S. crude futures were on track to gain nearly 10% in value. Investors also kept a close eye on retail stocks on the last day of shopping before the start of Christmas. A spike in online shopping has intensified pressure on shipping companies to deliver last-minute gifts on time, while brick and mortar shops have been forced to slash prices in order to attract more customers. A major storm throughout the Southern portions of the U.S. also contributed to mounting fears that thousands of customers might not receive their gifts in time for the holiday. Shares in FedEx Corporation (N:FDX) on Thursday lost roughly 0.70% to 149.65.

EquityObserver.com continuously monitors and scans the markets for day trading and swing trading signals on NASDAQ, NYSE, AMEX, OTCBB and Pink Sheet companies for its free e-newsletter subscribers. To receive real-time SMS alerts, Just Text The Word EQUITY To 555888 From Your Cell Phone.

Achillion Pharmaceuticals, Inc.(NASDAQ:ACHN) increased 1.48% and close at $10.28 in the last trading session with the overall traded volume of 609,625 shares, versus the average volume of 2.15 million shares. Its fifty two week range was $6.41-$16.54. It has market cap of $1.38 billion while its total outstanding shares are 136.54 million. Achillion Pharmaceuticals, Inc.(NASDAQ:ACHN) on December 21, 2015 gained 1.55% to close Friday’s session at USD 9.81. The shares of the company moved in the range of USD 9.47 and USD 9.99. A trading volume of 4.20 million shares was recorded, which was greater than its 150-day daily average volume of 2.85 million shares and its 52-week average volume of 3.78 million shares. Over the last five days Achillion Pharmaceuticals Inc.’s shares have advanced 6.40%, whereas in the past one month the stock has lost 1.70%. Additionally, over the last six months the shares have registered a profit of 11.60%. The company has returned 12.89% in the last three months, on a compounded total return basis. The stock is trading at a price to book (MRQ) ratio of 3.07, which compares to a historical PB ratio near to 8.85. Further, the stock is trading at a price to sales (TTM) ratio of 38.20.

Is ACHN a Solid Investment at These Levels? Read This Report For Details

Threshold Pharmaceuticals, Inc.(NASDAQ:THLD) moved down -0.22% with the closing price of $0.502. The overall volume in the last trading session was 607,871.00 shares. Its fifty two week range was $0.45-$5.28. The total market capitalization remained $35.97 million while its total outstanding shares are 71.46 million. Threshold Pharmaceuticals, Inc.(NASDAQ:THLD) on Dec 18, 2015 announced that it has initiated a significant reduction in its workforce in order to focus the company’s financial resources in the near term on two ongoing Phase 2 proof-of-concept clinical trials of tarloxotinib bromide company’s novel epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) licensed from the University of Auckland, New Zealand. Threshold will reduce its workforce by approximately two-thirds, resulting in between 20-25 remaining employees. Threshold anticipates the one-time severance-related charge associated with the workforce reduction to be approximately $2.6 million, which includes approximately $0.3 million of non-cash expense related to the extension of the post-termination exercise period for the outstanding vested stock options for the affected employees. The majority of the charges will be paid by the end of the first quarter of 2016.

How Should Investors Trade THLD Now? Don’t Miss out a Special Trend Analysis

Keryx Biopharmaceuticals(NASDAQ:KERX) decreased -0.19% to close at $5.38 in the last trading session and its total traded volume was 602,553.00 shares versus average volume of 1.82 million. The company has market cap of $566.99 million while its total outstanding shares are 105.19 million. Keryx Biopharmaceuticals(NASDAQ:KERX) on Dec. 22, 2015 a biopharmaceutical company focused on bringing innovative therapies to market for people with renal disease, announced it will present at the 34thAnnual J.P. Morgan Healthcare Conference in San Francisco on Monday, January 11, 2016 at 9:30 a.m. PST (12:30 p.m. PST). A live audio webcast of both the presentation and immediately following breakout session will be accessible from Keryx’s website at http://investors.keryx.com within the Investor Relations section under the “webcasts and presentations” page. An archived version of the webcast will be available for at least 15 days following the conclusion of the live presentation and breakout session.

Can KERX Show a Strong Recovery? Find out in This Research Report

EquityObserver.com continuously monitors and scans the markets for day trading and swing trading signals on NASDAQ, NYSE, AMEX, OTCBB and Pink Sheet companies for its free e-newsletter subscribers. To receive real-time SMS alerts, Just Text The Word EQUITY To 555888 From Your Cell Phone.